Senti Biosciences Stock (NASDAQ:SNTI)
Previous Close
$2.18
52W Range
$1.52 - $7.43
50D Avg
$2.40
200D Avg
$3.04
Market Cap
$9.73M
Avg Vol (3M)
$21.70K
Beta
2.75
Div Yield
-
SNTI Company Profile
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
SNTI Performance
Peer Comparison
Ticker | Company |
---|---|
BLCM | Bellicum Pharmaceuticals, Inc. |
MNPR | Monopar Therapeutics Inc. |
FHTX | Foghorn Therapeutics Inc. |
MLYS | Mineralys Therapeutics, Inc. |
SABS | SAB Biotherapeutics, Inc. |
CVKD | Cadrenal Therapeutics, Inc. Common Stock |
QNRX | Quoin Pharmaceuticals, Ltd. |
FENC | Fennec Pharmaceuticals Inc. |
HILS | Tharimmune, Inc. |
TYRA | Tyra Biosciences, Inc. |
CING | Cingulate Inc. |
CNTB | Connect Biopharma Holdings Limited |
XLO | Xilio Therapeutics, Inc. |
LIPO | Lipella Pharmaceuticals Inc. |
NLTX | Neurogene Inc. |
RAPT | RAPT Therapeutics, Inc. |